Table 3.

Published reports of eculizumab use in C3 glomerulopathy and MPGN

Report (year)	Study design	Reported diagnosis (age at treatment/sex)	C3NeF	Treatment duration (months)	Clinical response
Daina et al. (2012) [18]	Case report	DDD (22F)	+	11	Yes
Vivarelli et al. (2012) [19]	Case report	DDD (17M)	+	18 + 9	Yes
Radhakrishnan et al. (2012) [20]	Case report	MPGN Type 1 (16F)	+	1.5	Yes
McCaughan et al. (2012) [21]	Case report	Allograft recurrent DDD (29F)	+	2.5	Yes
Bomback et al. (2012) [22]	Prospective, open-label, uncontrolled trial	DDD (22M)	−	12	Yes	50%	82%
		DDD (42M)	+	9	No
		Allograft recurrent DDD (32M)	−	12	Yes
		C3GN (25M)	−	12	No
		Allograft recurrent C3GN (22M)	+	12	No
		Allograft recurrent C3GN (20M)	+	12	Yes
Gurkan et al. (2013) [23]	Case report	Allograft recurrent C3GN (21M)	+	12	Yes
Besbas et al. (2013) [24]	Case report	C3 glomerulopathy (16F)	−	10	No
Kerns et al. (2013) [25]	Case report	C3 glomerulopathy (16M)	−	3.5	Yes
Rousset-Rouvière et al. (2014) [26]	Case report	DDD (10M)	+	6.5	Yes
Ozkaya (2014) et al. [27]	Case report	DDD (14F)	+	7	Yes
Berthe-Aucejo et al. (2014) [28]	Case report	DDD (17M)	+	3.5	No
Sánchez-Moreno et al. (2014) [29]	Case report	Allograft recurrent DDD (14F)	+	30	Yes